Clinical Trial

A Study of EDG-5506 in Children With Duchenne Muscular Dystrophy (LYNX)

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The LYNX study is a 2-part, multicenter, Phase 2 study of safety, pharmacokinetics and biomarkers in children with Duchenne muscular dystrophy including a randomized, double-blind, placebo-controlled part A, followed by an open-label part B.
Protocol Amendment History 17 amendments
This ClinicalTrials.gov record has been amended 17 times since 2022-09-12; most recent amendment 2025-11-10.
Status change: Recruiting → Active, Not Recruiting 2024-12-20
Status change: Not Yet Recruiting → Recruiting 2022-10-24
Trial Details
NCT Number NCT05540860
Lead Sponsor Edgewise Therapeutics, Inc.
Conditions Duchenne Muscular Dystrophy
Enrollment 76 participants
Start Date 2022-10-24
Primary Completion 2027-01 (estimated)
Study Completion 2027-01 (estimated)
Updated on ClinicalTrials.gov 2025-11-12